Does adjuvant chemotherapy in elderly patients with stage III colon cancer really save lives?

Journal of Clinical Oncology

Volumn 31, Issue 4, 2013, Pages 511-512

  Wong, Hui Li ^a   Gibbs, Peter ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b Western Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; COLON CANCER; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; COLON TUMOR; FEMALE; MALE; MORTALITY; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE;

EID: 84874762369     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.7770     Document Type: Letter

References (11)

1. Sanoff HK, Carpenter WR, Stürmer T, et al: Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 30: 2624-2634, 2012
2. Francini G, Petrioli R, Lorenzini L, et al: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 106: 899-906, 1994 (Pubitemid 24109275)
3. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22: 1797-1806, 2004 (Pubitemid 41095169)
4. André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27: 3109-3116, 2009
5. Yothers G, O'Connell MJ, Allegra CJ, et al: Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29: 3768-3774, 2011
6. Muss HB, Bynum DL: Adjuvant chemotherapy in older patients with stage III colon cancer: An underused lifesaving treatment. J Clin Oncol 30: 2576-2578, 2012
7. Field KM, Kosmider S, Jefford M, et al: Chemotherapy dosing strategies in the obese, elderly, and thin patient: Results of a nationwide survey. J Oncol Pract 4: 108-113, 2008 (Pubitemid 351952696)
8. Lyman GH: Weight-based chemotherapy dosing in obese patients with cancer: Back to the future. J Oncol Pract 8:62e-64e, 2012
9. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257, 2003 (Pubitemid 36859476)
10. Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28: 3219-3226, 2010
11. Tie J, Gibbs P, Lipton L, et al: Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 128: 2075-2084, 2011